MULTICENTER NETWORK OF NEONATAL INTENSIVE CARE UNITS

我们要求继续参加NICHD合作新生儿 研究网络。我们的主要优势包括： L)患者人数众多。1994年，我们有16,742名新生儿，291名极低出生体重 婴儿和1450名新生儿ICU住院(97%是出生的)。充分有效 我们的婴儿参与网络试验是由我们的 教职员工的保守治疗理念。 2)高素质的PI。泰森博士在以下领域拥有丰富经验 多中心试验，在实验设计方面的非凡专业知识，以及 对卫生政策、卫生保健中的“前沿”问题的不同寻常的了解 经济学和成果研究。他不仅是儿科学教授 达拉斯得克萨斯大学西南分校的兼职教授 他所在的休斯顿公共卫生学院的流行病学 1993-1994年在卫生政策研究所担任客座教授。 3)在网络中有良好的记录。我们在这两个方面都名列前茅 在网络中注册的合格婴儿的百分比和总注册百分比 过去10年的研究。我们的私家侦探做出了很大贡献， 设计了下一次重大试验，试验将持续大约16年 3个月，并在两个资助期之间架起桥梁。在下一个资助期，他 已提议进行一项得到指导委员会认可的大型试验，以减少 婴儿的资源利用、创伤、辐射和医院感染 等于或小于1000克体重。 4)其他主要优势。这些包括a)高生产力的新生儿 部门；b)具有丰富经验的围产期合作者 管理试验和围产期网络应用中的PI C)一个广泛和组织良好的新生儿数据库，已证明具有以下价值 网络；和d)一个后续诊所，它不仅在 观察性研究，以及后续干预的主要试验， 例如初级保健试验(由卫生保健政策机构资助 和研究)和婴儿健康和发展方案(由 NICHD和罗伯特·伍德·约翰逊基金会)。

We request continued participation in the NICHD Cooperative Neonatal Research Network. Our major strengths include: l) A large patient population. In 1994 we had 16,742 births, 291 VLBW infants, and 1450 neonatal ICU admissions (97% inborn). Full and effective participation of our infants in Network trials is fostered by our faculty's conservative treatment philosophy. 2) A highly qualified PI. Dr. Tyson has extensive experience in multicenter trials, unusual expertise in experimental design, and an uncommon knowledge of "cutting edge" issues in health policy, health care economics, and outcomes research. He is not only Professor of Pediatrics and Obstetrics at UT Southwestern in Dallas but also Adjunct Professor of Epidemiology at the School of Public Health in Houston where he was Visiting Professor at the Health Policy Institute during 1993-1994. 3) A strong track record in the Network. We have ranked high in both percent of eligible infants enrolled and in total enrollment in Network studies during the past 10 years. Our PI has contributed heavily and has designed the next major trial, a trial that will last approximately 16 months and bridge the 2 funding periods. For the next funding period, he has proposed a major trial endorsed by the Steering Committee to reduce resource use, trauma, radiation, and nosocomial infection among infants equal to or less than 1000 g BW. 4) Other major strengths. These include a) a highly productive neonatal division; b) a perinatal collaborator who is quite experienced in large management trials and the PI in an application to the Perinatal Network; c) an extensive and well organized neonatal data base of proven value to the Network; and d) a follow-up clinic that has excelled in not only observational studies but also major trials of follow-up interventions, e.g. the Primary Care Trial (funded by the Agency for Health Care Policy and Research) and the Infant Health and Development Program (funded by NICHD and the Robert Wood Johnson Foundation).